• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    2/14/23 12:31:02 PM ET
    $BWV
    $FUSN
    $GOVX
    $GRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BWV alert in real time by email

    Gainers

    • Blue Water Vaccines (NASDAQ:BWV) stock moved upwards by 46.1% to $1.71 during Tuesday's regular session. Trading volume for this security as of 12:30 EST is 52.2 million, which is 15191.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $26.4 million.
    • Fusion Pharmaceuticals (NASDAQ:FUSN) shares rose 18.5% to $4.29. Fusion Pharmaceuticals's stock is trading at a volume of 12.1 million shares as of 12:30 EST. This is 13663.5% of its average full-day volume over the last 100 days. The company's market cap stands at $192.0 million.
    • Geovax Labs (NASDAQ:GOVX) shares rose 17.17% to $0.91. As of 12:30 EST, this security is trading at a volume of 1.5 million shares, making up 84.2% of its average full-day volume over the last 100 days. The company's market cap stands at $24.0 million.
    • Hyperfine (NASDAQ:HYPR) shares moved upwards by 16.26% to $1.43. The current volume of 23.9 million shares is 2838.8% of Hyperfine's average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $101.0 million.
    • Strata Skin Sciences (NASDAQ:SSKN) shares rose 16.14% to $1.37. Trading volume for Strata Skin Sciences's stock is 137.7K as of 12:30 EST. This is 1069.1% of its average full-day volume over the last 100 days. The company's market cap stands at $47.5 million.
    • Sesen Bio (NASDAQ:SESN) stock rose 13.33% to $0.61. Trading volume for Sesen Bio's stock is 1.4 million as of 12:30 EST. This is 138.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $123.7 million.

    Losers

    • T2 Biosystems (NASDAQ:TTOO) shares fell 22.5% to $1.08 during Tuesday's regular session. Trading volume for this security as of 12:30 EST is 1.8 million, which is 817.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $7.9 million.
    • Galera Therapeutics (NASDAQ:GRTX) shares fell 20.99% to $1.81. As of 12:30 EST, Galera Therapeutics's stock is trading at a volume of 459.5K, which is 406.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $51.5 million.
    • Entrada Therapeutics (NASDAQ:TRDA) shares fell 19.53% to $12.9. As of 12:30 EST, Entrada Therapeutics's stock is trading at a volume of 142.2K, which is 251.7% of its average full-day volume over the last 100 days. The company's market cap stands at $426.0 million.
    • Macrogenics (NASDAQ:MGNX) stock decreased by 17.8% to $5.22. As of 12:30 EST, Macrogenics's stock is trading at a volume of 675.6K, which is 93.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $320.9 million.
    • NanoVibronix (NASDAQ:NAOV) stock decreased by 17.66% to $4.29. NanoVibronix's stock is trading at a volume of 68.1K shares as of 12:30 EST. This is 52.2% of its average full-day volume over the last 100 days. The company's market cap stands at $7.0 million.
    • Ontrak (NASDAQ:OTRKP) stock declined by 16.11% to $1.25. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BWV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BWV
    $FUSN
    $GOVX
    $GRTX

    CompanyDatePrice TargetRatingAnalyst
    GeoVax Labs Inc.
    $GOVX
    2/19/2026Buy → Hold
    D. Boral Capital
    Entrada Therapeutics Inc.
    $TRDA
    2/11/2026$20.00Buy
    Guggenheim
    Entrada Therapeutics Inc.
    $TRDA
    1/28/2026$21.00Outperform
    Oppenheimer
    MacroGenics Inc.
    $MGNX
    9/17/2025$3.00Overweight
    Barclays
    GeoVax Labs Inc.
    $GOVX
    4/15/2025$18.00 → $14.00Buy
    D. Boral Capital
    GeoVax Labs Inc.
    $GOVX
    4/15/2025$15.00 → $8.50Buy
    Alliance Global Partners
    Entrada Therapeutics Inc.
    $TRDA
    12/6/2024$29.00Buy
    ROTH MKM
    GeoVax Labs Inc.
    $GOVX
    11/11/2024$15.00Buy
    Alliance Global Partners
    More analyst ratings

    $BWV
    $FUSN
    $GOVX
    $GRTX
    SEC Filings

    View All

    SEC Form 10-K filed by Galera Therapeutics Inc.

    10-K - Galera Therapeutics, Inc. (0001563577) (Filer)

    3/19/26 7:15:26 AM ET
    $GRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Hyperfine Inc.

    S-8 - Hyperfine, Inc. (0001833769) (Filer)

    3/18/26 4:29:05 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-K filed by Hyperfine Inc.

    10-K - Hyperfine, Inc. (0001833769) (Filer)

    3/18/26 4:21:55 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BWV
    $FUSN
    $GOVX
    $GRTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Baker Bros. Advisors Lp bought $261,846 worth of shares (28,867 units at $9.07) (SEC Form 4)

    4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

    11/24/25 4:09:49 PM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Rubinstein Samuel sold $18,804 worth of shares (14,094 units at $1.33) and bought $7,028 worth of shares (5,000 units at $1.41), decreasing direct ownership by 51% to 8,766 units (SEC Form 4)

    4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

    11/18/25 4:35:42 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    Large owner Baker Bros. Advisors Lp bought $1,352,587 worth of shares (178,044 units at $7.60) (SEC Form 4)

    4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

    11/12/25 5:34:18 PM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BWV
    $FUSN
    $GOVX
    $GRTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Entrada Therapeutics Inc.

    4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

    3/11/26 4:35:13 PM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Entrada Therapeutics Inc.

    4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

    3/11/26 4:34:08 PM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Wentworth Kory James sold $97,892 worth of shares (7,988 units at $12.25), decreasing direct ownership by 5% to 137,987 units (SEC Form 4)

    4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

    3/6/26 4:36:45 PM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BWV
    $FUSN
    $GOVX
    $GRTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    GeoVax Labs downgraded by D. Boral Capital

    D. Boral Capital downgraded GeoVax Labs from Buy to Hold

    2/19/26 8:44:06 AM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Entrada Therapeutics with a new price target

    Guggenheim initiated coverage of Entrada Therapeutics with a rating of Buy and set a new price target of $20.00

    2/11/26 7:51:55 AM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Entrada Therapeutics with a new price target

    Oppenheimer initiated coverage of Entrada Therapeutics with a rating of Outperform and set a new price target of $21.00

    1/28/26 7:58:46 AM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BWV
    $FUSN
    $GOVX
    $GRTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hyperfine, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

    Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced fourth quarter and full year 2025 financial results and provided a business update. "The launch of our second-generation Swoop® scanner, our Optive AI™ software, and the addition of a new market in the neurology office setting in mid-2025 marks a new era in the adoption of portable brain MRI and the future of our company. We hold a highly proprietary and differentiated technology leadership position in the ability to produce diagnostic quality images with an

    3/18/26 4:05:00 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures

    Initial MGC026 (B7-H3 ADC) Phase 1 results in mid-2026Initial MGC028 (ADAM9 ADC) Phase 1 results in second half of 2026Lorigerlimab Phase 2 LINNET study update in mid-2026IND submission for MGC030, a first-in-class TOP1i-based ADC, on track for 3Q 2026Cash, cash equivalents and marketable securities of $189.9 million as of December 31, 2025; cash runway guidance remains into late 2027 ROCKVILLE, Md., March 09, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress, reported financial results for th

    3/9/26 4:01:00 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hyperfine, Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026

    Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced that it will report financial results for the fourth quarter and full year 2025 on Wednesday, March 18, 2026. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call. F

    3/5/26 4:05:00 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BWV
    $FUSN
    $GOVX
    $GRTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for MARGENZA issued to MACROGENICS INC

    Submission status for MACROGENICS INC's drug MARGENZA (SUPPL-5) with active ingredient MARGETUXIMAB-CMKB has changed to 'Approval' on 05/25/2023. Application Category: BLA, Application Number: 761150, Application Classification:

    5/29/23 4:45:45 AM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for MARGENZA

    Submission status for MACROGENICS INC's drug MARGENZA (ORIG-1) with active ingredient MARGETUXIMAB-CMKB has changed to 'Approval' on 12/16/2020. Application Category: BLA, Application Number: 761150, Application Classification:

    12/20/20 4:31:01 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BWV
    $FUSN
    $GOVX
    $GRTX
    Leadership Updates

    Live Leadership Updates

    View All

    ENvue Medical Appoints Industry Veteran Marc Waldman as Vice President, Commercial

    TYLER, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ:FEED) (NASDAQ:NAOV) ("ENvue," "ENvue Medical" or the "Company"), a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings, today announced the appointment of Marc Waldman as Vice President, Commercial. In this role, Mr. Waldman will lead ENvue's U.S. commercialization strategy, with a focus on expanding its existing presence in 38 hospitals and accelerating revenue across the Company's enteral platform. "Marc is a highly accomplished sales leader with extensive GPO and IDN expertise and long-standing relationships th

    1/21/26 8:30:00 AM ET
    $FEED
    $NAOV
    Industrial Specialties
    Health Care

    Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the appointment of Maria Sainz to its Board of Directors effective as of January 9, 2026. "We are delighted to welcome Maria to our Board of Directors," said Pulse Biosciences' Co-Chairman of the Board Robert W. Duggan. "She brings an exceptionally strong track record of guiding both public and private medical device companies through growth, commercialization, viability, and scale. Her strategic and operational expertise will be invaluable as Pulse begins creating and disrupting interventional m

    1/9/26 7:00:00 AM ET
    $AVNS
    $HYPR
    $OFIX
    Industrial Specialties
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

    MacroGenics Appoints Eric Risser as President and Chief Executive Officer

    ROCKVILLE, MD, Aug. 13, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company developing innovative antibody-based therapeutics for the treatment of cancer, today announced that effective as of August 13, 2025, Eric Risser has been appointed President, Chief Executive Officer and to the Board of Directors. Mr. Risser has served as Chief Operating Officer at MacroGenics since 2022, overseeing several key company functions and has led the Company's corporate development efforts, which have generated over $1.6 billion in non-dilutive capital since inception. Mr. Risser succeeds Scott Koenig, M.D., Ph.D. who is stepping down after serving as Presi

    8/13/25 4:01:00 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BWV
    $FUSN
    $GOVX
    $GRTX
    Financials

    Live finance-specific insights

    View All

    Hyperfine, Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026

    Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced that it will report financial results for the fourth quarter and full year 2025 on Wednesday, March 18, 2026. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call. F

    3/5/26 4:05:00 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Hyperfine Announces FDA Clearance of the First Optive AI™ Software Update with Advanced Diffusion Imaging Capability, Focused on Enhancing Stroke Detection with the Swoop® System

    A new multi-direction DWI sequence, the latest Swoop® system software, and the first advancement in Hyperfine's Optive AI™ software, delivers clearer, higher-quality images for stroke diagnosis, enhancing the value of the Swoop® system in acute neurological care. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced that it has received FDA clearance for a new multi-direction diffusion-weighted imaging (DWI) software sequence. This advancement delivers substantially improved image quality and diagnostic confidence for stroke detect

    12/15/25 8:15:00 AM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    STRATA Skin Sciences to Report Third Quarter 2025 Financial Results on November 13, 2025 and Provide Corporate Update

    HORSHAM, Penn., Nov. 05, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report third quarter 2025 financial results on Thursday, November 13, 2025 after the market close. STRATA management will subsequently host a conference call at 4:30 p.m. ET on Thursday, November 13, 2025 to review financial results and provide an update on corporate developments. Following management's formal remarks, there will be a question-and-answer session. To listen to the conference call, in

    11/5/25 8:00:00 AM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    $BWV
    $FUSN
    $GOVX
    $GRTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by MacroGenics Inc.

    SC 13G - MACROGENICS INC (0001125345) (Subject)

    11/20/24 10:44:27 AM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by NanoVibronix Inc.

    SC 13G/A - NanoVibronix, Inc. (0001326706) (Subject)

    11/14/24 5:17:34 PM ET
    $NAOV
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13G/A filed by MacroGenics Inc.

    SC 13G/A - MACROGENICS INC (0001125345) (Subject)

    11/14/24 5:13:06 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care